ATE492542T1 - Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas - Google Patents
Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitasInfo
- Publication number
- ATE492542T1 ATE492542T1 AT05812611T AT05812611T ATE492542T1 AT E492542 T1 ATE492542 T1 AT E492542T1 AT 05812611 T AT05812611 T AT 05812611T AT 05812611 T AT05812611 T AT 05812611T AT E492542 T1 ATE492542 T1 AT E492542T1
- Authority
- AT
- Austria
- Prior art keywords
- biphenyl
- carbonylaminosic
- obesitas
- preparation
- treatment
- Prior art date
Links
- -1 BIPHENYL-4-YL Chemical class 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61897504P | 2004-10-15 | 2004-10-15 | |
| PCT/US2005/037215 WO2006044775A2 (en) | 2004-10-15 | 2005-10-14 | Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE492542T1 true ATE492542T1 (de) | 2011-01-15 |
Family
ID=36203612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05812611T ATE492542T1 (de) | 2004-10-15 | 2005-10-14 | Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7759376B2 (de) |
| EP (1) | EP1805156B1 (de) |
| JP (1) | JP2008516978A (de) |
| KR (1) | KR20070063546A (de) |
| CN (1) | CN101087769A (de) |
| AT (1) | ATE492542T1 (de) |
| AU (1) | AU2005295453A1 (de) |
| BR (1) | BRPI0516483A (de) |
| CA (1) | CA2583784A1 (de) |
| CR (1) | CR9034A (de) |
| DE (1) | DE602005025517D1 (de) |
| EA (1) | EA200700851A1 (de) |
| EC (1) | ECSP077397A (de) |
| ES (1) | ES2357015T3 (de) |
| IL (1) | IL182218A0 (de) |
| MA (1) | MA28935B1 (de) |
| MX (1) | MX2007004217A (de) |
| NO (1) | NO20072461L (de) |
| TN (1) | TNSN07111A1 (de) |
| WO (1) | WO2006044775A2 (de) |
| ZA (1) | ZA200703002B (de) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7795283B2 (en) | 2004-12-14 | 2010-09-14 | Astrazeneca Ab | Oxadiazole derivative as DGAT inhibitors |
| EP1973920B1 (de) | 2005-11-21 | 2010-07-21 | Anadys Pharmaceuticals, Inc. | Neues verfahren zur herstellung von 5-amino-3h-thiazolo[4,5-d]pyrimidin-2-on |
| JP2009520786A (ja) | 2005-12-22 | 2009-05-28 | アストラゼネカ アクチボラグ | Ｄｇａｔ阻害剤として使用するためのピリミド−［４，５−ｂ］−オキサジン |
| PT2402319T (pt) | 2006-03-31 | 2017-12-11 | Novartis Ag | Inibidores de dgat |
| US8084478B2 (en) | 2006-05-30 | 2011-12-27 | Asstrazeneca Ab | Substituted 5- phenylamino- 1, 3, 4-oxadiazol-2-ylcarbonylamino-4-phenoxy-cyclohexane carboxylic acid as inhibitors of acetyl coenzyme A diacylglycerol acyltransferase |
| AU2007266890B2 (en) | 2006-05-30 | 2011-02-17 | Astrazeneca Ab | 1, 3, 4 -oxadiazole derivatives as DGAT1 inhibitors |
| KR100811100B1 (ko) | 2006-09-27 | 2008-03-06 | 한국생명공학연구원 | 벤즈아졸 유도체를 유효성분으로 함유하는 대사성 질환예방 및 치료용 약학적 조성물 |
| KR100795462B1 (ko) | 2006-09-27 | 2008-01-16 | 한국생명공학연구원 | 인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물 |
| AR063311A1 (es) | 2006-10-18 | 2009-01-21 | Novartis Ag | Compuestos organicos |
| BRPI0720023A2 (pt) * | 2006-12-11 | 2018-09-04 | Novartis Ag | método para prevenir ou tratar isquemia do miocárdio por inibição da enzima dgat1 com um inibidor de dgat1 |
| CL2008001671A1 (es) | 2007-06-08 | 2009-07-17 | Janssen Pharmaceutica Nv | Compuestos derivados de piperidina/piperazina inhibidores de dgat1, composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades metabolicas especialmente diabetes. |
| US8835437B2 (en) | 2007-06-08 | 2014-09-16 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
| CA2687918C (en) * | 2007-06-08 | 2016-11-08 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
| JO2972B1 (en) | 2007-06-08 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Piperidine / piperazine derivatives |
| AR066169A1 (es) | 2007-09-28 | 2009-07-29 | Novartis Ag | Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat |
| ES2535083T3 (es) | 2007-12-20 | 2015-05-05 | Astrazeneca Ab | Compuestos de carbamoilo como inhibidores 190 de DGAT1 |
| AU2009243756B2 (en) | 2008-05-05 | 2013-06-27 | Sanofi-Aventis | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals |
| EP2296659B1 (de) | 2008-06-05 | 2016-12-21 | Janssen Pharmaceutica, N.V. | Einen DGAT-Inhibitor und einen PPAR-Agonisten enthaltende Arzneikombinationen |
| US20100168079A1 (en) * | 2008-12-23 | 2010-07-01 | Daniela Angst | Biaryl Benzylamine Derivatives |
| CA2749700A1 (en) * | 2009-01-23 | 2010-07-29 | Msd K.K. | Benzodiazepin-2-on derivatives |
| EP3366686B9 (de) | 2009-03-20 | 2021-08-04 | Metabasis Therapeutics, Inc. | Inhibitoren von diacylglycerin-o-acyltransferase 1 (dgat-1) und verwendungen davon |
| US8268820B2 (en) * | 2009-03-26 | 2012-09-18 | Hoffmann-La Roche Inc. | 2,3-diaryl- or heteroaryl-substituted 1,1,1-trifluoro-2-hydroxypropyl compounds |
| US20100256153A1 (en) | 2009-03-27 | 2010-10-07 | Bristol-Myers Squibb Company | Methods for preventing or reducing risk of mortality |
| WO2010146395A1 (en) | 2009-06-19 | 2010-12-23 | Astrazeneca Ab | Pyrazine carboxamides as inhibitors of dgat1 |
| AR079022A1 (es) * | 2009-11-02 | 2011-12-21 | Sanofi Aventis | Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion |
| US8722901B2 (en) | 2009-11-05 | 2014-05-13 | Piramal Enterprises Limited | Carboxy oxazole or thiazole compounds as DGAT-1 inhibitors useful for the treatment of obesity |
| BR112012014196B1 (pt) * | 2009-12-16 | 2023-10-03 | Pola Chemical Industries Inc | Agente para prevenir ou melhorar a pigmentação |
| AU2011235301B2 (en) | 2010-03-30 | 2013-07-18 | Novartis Ag | Uses of DGAT1 inhibitors |
| WO2012150784A2 (ko) | 2011-05-03 | 2012-11-08 | 한국생명공학연구원 | 신규한 인돌 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물 |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US9499482B2 (en) | 2012-09-05 | 2016-11-22 | Bristol-Myers Squibb Company | Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists |
| WO2014039411A1 (en) | 2012-09-05 | 2014-03-13 | Bristol-Myers Squibb Company | Pyrrolone or pyrrolidinone melanin concentrating hormore receptor-1 antagonists |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| ES2828704T3 (es) * | 2014-08-01 | 2021-05-27 | Bayer Pharma AG | Procedimiento para la preparación de (4S)-4-(4-ciano-2-metoxifenil)-5-etoxi-2,8-dimetil-1,4-dihidro-1,6-naftiridin-3-carboxamida y su purificación para su uso como principio activo farmacéutico |
| CN105646510A (zh) * | 2014-12-02 | 2016-06-08 | 重庆宁牧生态农业有限公司 | 一种用作抗肥胖剂的化合物 |
| EP3983084A1 (de) * | 2019-06-12 | 2022-04-20 | Vanderbilt University | Aminosäuretransportinhibitoren und deren verwendungen |
| CN112336718A (zh) * | 2020-10-19 | 2021-02-09 | 济南大学 | 一种苯并咪唑衍生物作为α-葡萄糖苷酶抑制剂及其应用 |
| WO2023085931A1 (en) | 2021-11-11 | 2023-05-19 | Koninklijke Nederlandse Akademie Van Wetenschappen | Hepatic organoids |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4164645B2 (ja) * | 2002-08-09 | 2008-10-15 | 株式会社大塚製薬工場 | Ｄｇａｔ阻害剤 |
| MXPA05005425A (es) * | 2002-11-22 | 2005-11-23 | Japan Tobacco Inc | Heterociclos que contienen nitrogeno, biciclicos, fusionados. |
| AR044152A1 (es) * | 2003-05-09 | 2005-08-24 | Bayer Corp | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad |
-
2005
- 2005-10-14 AU AU2005295453A patent/AU2005295453A1/en not_active Abandoned
- 2005-10-14 WO PCT/US2005/037215 patent/WO2006044775A2/en active Application Filing
- 2005-10-14 US US11/665,317 patent/US7759376B2/en not_active Expired - Fee Related
- 2005-10-14 CA CA002583784A patent/CA2583784A1/en not_active Abandoned
- 2005-10-14 JP JP2007536988A patent/JP2008516978A/ja active Pending
- 2005-10-14 ES ES05812611T patent/ES2357015T3/es active Active
- 2005-10-14 MX MX2007004217A patent/MX2007004217A/es not_active Application Discontinuation
- 2005-10-14 KR KR1020077008522A patent/KR20070063546A/ko not_active Application Discontinuation
- 2005-10-14 EP EP05812611A patent/EP1805156B1/de not_active Not-in-force
- 2005-10-14 CN CNA2005800433280A patent/CN101087769A/zh active Pending
- 2005-10-14 AT AT05812611T patent/ATE492542T1/de not_active IP Right Cessation
- 2005-10-14 EA EA200700851A patent/EA200700851A1/ru unknown
- 2005-10-14 DE DE602005025517T patent/DE602005025517D1/de active Active
- 2005-10-14 BR BRPI0516483-4A patent/BRPI0516483A/pt not_active IP Right Cessation
-
2007
- 2007-03-27 IL IL182218A patent/IL182218A0/en unknown
- 2007-03-28 TN TNP2007000111A patent/TNSN07111A1/en unknown
- 2007-03-30 CR CR9034A patent/CR9034A/es not_active Application Discontinuation
- 2007-04-12 ZA ZA200703002A patent/ZA200703002B/xx unknown
- 2007-04-13 EC EC2007007397A patent/ECSP077397A/es unknown
- 2007-04-17 MA MA29831A patent/MA28935B1/fr unknown
- 2007-05-14 NO NO20072461A patent/NO20072461L/no not_active Application Discontinuation
-
2010
- 2010-07-14 US US12/836,035 patent/US20110118302A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TNSN07111A1 (en) | 2008-06-02 |
| EP1805156A4 (de) | 2009-06-10 |
| EA200700851A1 (ru) | 2007-12-28 |
| IL182218A0 (en) | 2007-09-20 |
| US7759376B2 (en) | 2010-07-20 |
| ZA200703002B (en) | 2008-08-27 |
| US20070265298A1 (en) | 2007-11-15 |
| CN101087769A (zh) | 2007-12-12 |
| ECSP077397A (es) | 2007-05-30 |
| CR9034A (es) | 2008-11-18 |
| ES2357015T3 (es) | 2011-04-15 |
| KR20070063546A (ko) | 2007-06-19 |
| NO20072461L (no) | 2007-07-03 |
| MA28935B1 (fr) | 2007-10-01 |
| MX2007004217A (es) | 2007-06-11 |
| DE602005025517D1 (de) | 2011-02-03 |
| WO2006044775A2 (en) | 2006-04-27 |
| JP2008516978A (ja) | 2008-05-22 |
| EP1805156B1 (de) | 2010-12-22 |
| WO2006044775A3 (en) | 2006-06-15 |
| CA2583784A1 (en) | 2006-04-27 |
| US20110118302A1 (en) | 2011-05-19 |
| BRPI0516483A (pt) | 2008-09-02 |
| EP1805156A2 (de) | 2007-07-11 |
| AU2005295453A1 (en) | 2006-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE492542T1 (de) | Herstellung und anwendung von biphenyl-4-yl- carbonylaminosäurederivaten zur behandlung von obesitas | |
| MXPA05012061A (es) | Preparacion y uso de derivados alquilarilo para el tratamiento de la obesidad. | |
| EA200900802A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| EA200600078A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| WO2007016538A3 (en) | Preparation and use of biphenyl amino acid derivatives for the treatment of obesity | |
| DE602004020072D1 (de) | 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen | |
| ATE519488T1 (de) | Aminopyrazin-analoga zur behandlung von glaukomen und anderen durch rho-kinase verursachten krankheiten | |
| TW200730515A (en) | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | |
| DE60303238D1 (de) | Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten | |
| ATE544748T1 (de) | Zusammensetzungen und verfahren für die behandlung von zellproliferationserkrankungen | |
| ATE447551T1 (de) | Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen | |
| NO20064325L (no) | Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes | |
| ATE432278T1 (de) | Verbindungen zur behandlung von krankheiten | |
| WO2007095050A3 (en) | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase | |
| DE502005010499D1 (de) | Implantat zur Behandlung von Fettsucht | |
| ATE538651T1 (de) | Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit | |
| ATE389395T1 (de) | Substituierte 2-aminotetraline zur vorbeugenden behandlung von morbus parkinson | |
| DE602005018366D1 (de) | Zur behandlung von auf eine modulation des dopamin-d3-rezeptors ansprechende erkrankungen geeignete 4-piperazinylpyrimidinverbindungen | |
| DE602006003094D1 (de) | 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit | |
| DE602005016141D1 (de) | S-mirtazapin zur behandlung von hitzewallungen | |
| DE602004021358D1 (de) | Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen | |
| DE602005014632D1 (de) | Pyrrol- bzw. imidazolamide zur behandlung von obesitas | |
| ATE448779T1 (de) | Methode zur behandlung trockener augen und uveitis | |
| DE602005027228D1 (de) | Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind | |
| ATE361071T1 (de) | Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |